- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
BioForce Nanosciences,Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc.
(OTC Bulletin Board: BFNH.OB), announced that it exceeded its 2006 goal for
shipping up to 20 of its cutting-edge Nano eNabler(TM) molecular printers
to prestigious institutions across the globe. BioForce exceeded its goal by
two units by year end. These pilot placements of the Company's patented
Nano eNabler device at centers of research excellence, allow the
entrepreneurial researchers at those centers to act as "early adopters" of
BioForce's practical tools and technologies.
"With the shipment of these 22 Nano eNabler molecular printers," says
BioForce Product Manager Michael Lynch, "BioForce is now essentially
partnering with an impressive group of innovators working in the micro and
nanotechnology fields. Several groups have already expressed a desire to
seek funds to convert their placement into a purchase."
Kerry Frey, BioForce's chief operating officer, says, "BioForce
Nanosciences is positioned between two very exciting markets-nanotechnology
and the life sciences. We strongly believe our Nano eNabler system will
change how research is conducted in laboratories across the world." He
explains that the ease of use and practicality provided by the Nano eNabler
system, establish a path from laboratory to industry.
Institutions where recent placements have taken place:
* University of California, Cal-it2, Irvine, CA
* Cornell University, NanoBioTechnology Center, Ithaca, NY
* ETH Zurich, Zurich, Switzerland
* Georgia Institute of Technology, Microelectronics Research Center,
* Stanford University, James H. Clark Center, Stanford, CA
About BioForce Nanosciences
BioForce Nanosciences, Inc. is a wholly owned subsidiary of BioForce
Nanosciences Holdings, Inc. (OTC Bulletin Board: BFNH.OB). BioForce
Nanosciences is a unique company entering into commercialization with over
a decade of research and accomplishment in the field of bionanotechnology.
BioForce has demonstrated the ability to take a product from concept to
commercial sale. For more information, visit http://www.bioforcenano.com.
This news release contains forward-looking information that may be
affected by certain risks and uncertainties, including those risks and
uncertainties described in the Company's most recent filings with the
Securities and Exchange Commission. The Company's actual results could
differ materially from such forward-looking statements. We assume no duty
to update these statements at any future date.
For more information, please click here
Copyright © PR NewswireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
A nano-roundabout for light December 10th, 2016
Chemical trickery corrals 'hyperactive' metal-oxide cluster December 8th, 2016
Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016
Controlled electron pulses November 30th, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016
Nanobiotix revenue for Q2 2016 July 14th, 2016